Association of copper transporter expression with platinum resistance in epithelial ovarian cancer.

Abstract

BACKGROUND:

Copper transporters (CTR) also regulate the cellular transport of platinum drugs, but their role in platinum resistance of ovarian cancer has not been elucidated.

MATERIALS AND METHODS:

CTR expression in ovarian cancer tissues resected from patients treated by platinum-based chemotherapy was evaluated immunohistochemically. CTR2 expression in ovarian cancer cells was inhibited by bathocuproine disulfonate, and the changes in cisplatin sensitivity were examined.

RESULTS:

CTR2 expression was increased in chemoresistant patients, but not significantly. However, the CTR2/CTR1 ratio was significantly increased in chemoresistant patients. Cases with positive CTR2 expression or positive CTR2/CTR1 ratio had poor prognoses. When the CTR2 expression in ovarian cancer cells was suppressed, sensitivity to cisplatin was significantly increased.

CONCLUSION:

These data suggest that CTR2 contributes to platinum resistance in ovarian cancer. The CTR2/CTR1 ratio is a useful marker for platinum sensitivity and a potential prognostic factor in patients with ovarian cancer.

• Authors: Hiroyuki Yoshida, Masatomo Teramae, Makoto Yamauchi, Takeshi Fukuda, Tomoyo Yasui, Toshiyuki Sumi, Ken-Ichi Honda, Osamu Ishiko
• Journal: Anticancer research (Anticancer Res) Vol. 33 Issue 4 Pg. 1409-14 (Apr 2013) ISSN: 1791-7530 [Electronic] Greece
• PMID: 23564780 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Cation Transport Proteins
• Copper Transporter 1
• SLC31 Proteins
• SLC31A1 protein, human
• SLC31A2 protein, human
• Cisplatin

Topics

• Adenocarcinoma, Clear Cell (drug therapy, metabolism, mortality)
• Adenocarcinoma, Mucinous (drug therapy, metabolism, mortality)
• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents (pharmacology)
• Cation Transport Proteins (metabolism)
• Cisplatin (pharmacology)
• Copper Transporter 1
• Cystadenocarcinoma, Serous (drug therapy, metabolism, mortality)
• Drug Resistance, Neoplasm
• Endometrial Neoplasms (drug therapy, metabolism, mortality)
• Female
• Fluorescent Antibody Technique
• Humans
• Immunoenzyme Techniques
• Middle Aged
• Neoplasm Staging
• Ovarian Neoplasms (drug therapy, metabolism, mortality)
• Prognosis
• Retrospective Studies
• SLC31 Proteins
• Survival Rate
• Tumor Cells, Cultured